Benefits And Science

Periodontitis is a strange fit for a longevity supplement, and also a surprisingly logical one. It is a chronic inflammatory […]

A 2026 Mayo Clinic study improved diabetic wound healing with fisetin, and it is the first senolytic shown to work applied after the injury. It was rubbed on the skin, and the senescence readout was messier than the headline suggests.

Fisetin raised testosterone and restored sperm counts in rats, but every one of those studies first poisoned the animals. When researchers tested fisetin in healthy animals and measured actual fertility, they found nothing.

Fisetin protects the brain in animal head injury models, and one study used a genetic knockout to prove the mechanism. Nearly all of it dosed before the injury or within 30 minutes of it, which is not how head injuries happen.

Fisetin was the most potent URAT1 inhibitor in a screen of dietary flavonoids, beating quercetin. That is a real finding, and it is not the mechanism most articles claim it has.

Fisetin reduced nerve pain in diabetic and chemotherapy-induced neuropathy models. It also made gabapentin, pregabalin and opioids work harder, which is the part that matters if you already take one of them.

Fisetin shrinks infarct size in rodent stroke models with unusual consistency across labs. It is also one of the areas where the gap between an animal model and a real emergency is widest.

Fisetin behaves like an antidepressant in mouse despair tests and raises brain serotonin and noradrenaline. Every study is an animal study, and the test used most often is the one with the worst track record of predicting human results.

Fisetin triggered hair regrowth on shaved mice by boosting TERT in skin cells. The detail that gets dropped from every summary: it was applied to the skin, not swallowed.

Fisetin blocks mast cell degranulation in cell and animal models of hives, anaphylaxis, and food allergy, through a receptor most antihistamines don’t touch. What it hasn’t done is get tested in a human with allergies.

One mouse study found fisetin reduced lung fibrosis. Another found it wasn’t much help. And fisetin failed to kill senescent human lung fibroblasts in the study that discovered it was senolytic. The full picture is messier than the headline.

Fisetin improved fatty liver in mice across several models, but almost every study injected it rather than feeding it, and no human trial has tested it for liver disease. Here’s what that actually means.